CÃ©cile V Denis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/73228/publications.pdf

Version: 2024-02-01

150 papers	8,206 citations	50276 46 h-index	49909 87 g-index
152 all docs	152 docs citations	152 times ranked	7673 citing authors

#	Article	IF	Citations
1	CD40L stabilizes arterial thrombi by a Î²3 integrinâ€“dependent mechanism. Nature Medicine, 2002, 8, 247-252.	30.7	698
2	A mouse model of severe von Willebrand disease: Defects in hemostasis and thrombosis. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9524-9529.	7.1	479
3	Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. Journal of Clinical Investigation, 2000, 106, 385-392.	8.2	422
4	The Clearance Mechanism of Chilled Blood Platelets. Cell, 2003, 112, 87-97.	28.9	394
5	P-Selectin Glycoprotein Ligand 1 (Psgl-1) Is Expressed on Platelets and Can Mediate Plateletâ€“Endothelial Interactions in Vivo. Journal of Experimental Medicine, 2000, 191, 1413-1422.	8.5	388
6	von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood, 2015, 125, 2019-2028.	1.4	296
7	Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?. Blood, 2017, 130, 2463-2468.	1.4	197
8	Localized reduction of atherosclerosis in von Willebrand factorâ€“deficient mice. Blood, 2001, 98, 1424-1428.	1.4	188
9	von Willebrand factor: the old, the new and the unknown. Journal of Thrombosis and Haemostasis, 2012, 10, 2428-2437.	3.8	185
10	von Willebrand factor and inflammation. Journal of Thrombosis and Haemostasis, 2017, 15, 1285-1294.	3.8	178
11	Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectinâ€“mediated neutrophil rolling. Blood, 2007, 109, 2936-2943.	1.4	163
12	Of von Willebrand factor and platelets. Cellular and Molecular Life Sciences, 2015, 72, 307-326.	5.4	157
13	Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 4072-4077.	7.1	154
14	P-selectin glycoprotein ligand 1 and Î²2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood, 2006, 108, 3746-3752.	1.4	152
15	An Experimental Model to Study the in Vivo Survival of von Willebrand Factor. Journal of Biological Chemistry, 2004, 279, 12102-12109.	3.4	132
16	Clearance mechanisms of von Willebrand factor and factor VIII. Journal of Thrombosis and Haemostasis, 2007, 5, 1353-1360.	3.8	131
17	Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood, 2008, 112, 1704-1712.	1.4	131
18	Potent Thrombolytic Effect of N -Acetylcysteine on Arterial Thrombi. Circulation, 2017, 136, 646-660.	1.6	112

#	Article	IF	Citations
19	Platelet Adhesion Receptors and Their Ligands in Mouse Models of Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 728-739.	2.4	107
20	Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood, 2012, 119, 2126-2134.	1.4	99
21	Increased metastatic potential of tumor cells in von Willebrand factorâ€deficient mice. Journal of Thrombosis and Haemostasis, 2006, 4, 519-526.	3.8	96
22	Arterial Pulsatility and Circulating vonÂWillebrand Factor in Patients onÂMechanical CirculatoryÂSupport. Journal of the American College of Cardiology, 2018, 71, 2106-2118.	2.8	86
23	Integrin Î± ₆ Î² ₁ Is the Main Receptor for Vascular Laminins and Plays a Role in Platelet Adhesion, Activation, and Arterial Thrombosis. Circulation, 2013, 128, 541-552.	1.6	85
24	Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factorâ€“deficient mice. Blood, 2000, 95, 1703-1708.	1.4	81
25	Molecular and Cellular Biology of von Willebrand Factor. International Journal of Hematology, 2002, 75, 3-8.	1.6	81
26	Cysteine-mutations in von Willebrand factor associated with increased clearance. Journal of Thrombosis and Haemostasis, 2005, 3, 2228-2237.	3.8	80
27	Vascular endothelial cell expression of JAK2^{V617F} is sufficient to promote a pro-thrombotic state due to increased P-selectin expression. Haematologica, 2019, 104, 70-81.	3.5	80
28	Role of von Willebrand factor in tumor metastasis. Thrombosis Research, 2007, 120, S64-S70.	1.7	76
29	Arterial thrombosis: relevance of a model with two levels of severity assessed by histologic, ultrastructural and functional characterization. Journal of Thrombosis and Haemostasis, 2010, 8, 173-184.	3.8	75
30	Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5. Haematologica, 2012, 97, 1855-1863.	3.5	70
31	Localization of von Willebrand factor binding domains to endothelial extracellular matrix and to type VI collagen.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993, 13, 398-406.	3.9	68
32	Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2Bâ€“associated thrombocytopenia. Blood, 2013, 122, 2893-2902.	1.4	68
33	Altered thrombus formation in von Willebrand factorâ€“deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIbIIIa. Blood, 2008, 112, 603-609.	1.4	67
34	GpIbÎ±-VWF blockade restores vessel patency by dissolving platelet aggregates formed under very high shear rate in mice. Blood, 2014, 123, 3354-3363.	1.4	64
35	Binding of von Willebrand Factor to Collagen and Glycoprotein Ibα, But Not to Glycoprotein IIb/IIIa, Contributes to Ischemic Stroke in Miceâ€”Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1949-1951.	2.4	63
36	Clearance of von Willebrand factor. Journal of Thrombosis and Haemostasis, 2013, 11, 202-211.	3.8	63

#	Article	IF	Citations
37	Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. Blood, 2007, 109, 2430-2437.	1.4	61
38	Characterization of the interaction between von Willebrand factor and osteoprotegerin. Journal of Thrombosis and Haemostasis, 2007, 5, 1956-1962.	3.8	60
39	Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B. Blood, 2010, 115, 4870-4877.	1.4	60
40	Identification of Galectin-1 and Galectin-3 as Novel Partners for Von Willebrand Factor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 894-901.	2.4	59
41	Blocking Von Willebrand Factor for Treatment of Cutaneous Inflammation. Journal of Investigative Dermatology, 2014, 134, 77-86.	0.7	59
42	Models for Prediction of Factor VIII Half-Life in Severe Haemophiliacs: Distinct Approaches for Blood Group O and Non-O Patients. PLoS ONE, 2009, 4, e6745.	2.5	56
43	Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. Blood, 2014, 124, 1136-1145.	1.4	51
44	Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice. Blood, 2015, 126, 1823-1830.	1.4	51
45	The contribution of platelet glycoprotein receptors to inflammatory bleeding prevention is stimulus and organ dependent. Haematologica, 2018, 103, e256-e258.	3.5	50
46	Factor VIII and von Willebrand factor â€“ too sweet for their own good. Haemophilia, 2010, 16, 194-199.	2.1	49
47	A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease. Medicine (United States), 2016, 95, e3038.	1.0	48
48	Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models. Blood, 2001, 97, 465-472.	1.4	46
49	Clearance of von Willebrand factor. Thrombosis and Haemostasis, 2008, 99, 271-278.	3.4	45
50	von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin Î±IIbÎ²3. Journal of Clinical Investigation, 2013, 123, 5071-5081.	8.2	42
51	Insights from von Willebrand disease animal models. Cellular and Molecular Life Sciences, 1999, 56, 977-990.	5.4	40
52	von Willebrand factor is a major determinant of ADAMTS-13 decrease during mouse sepsis induced by cecum ligation and puncture. Journal of Thrombosis and Haemostasis, 2009, 7, 843-850.	3.8	40
53	Transient von Willebrand factorâ€mediated platelet influx stimulates liver regeneration after partial hepatectomy in mice. Liver International, 2017, 37, 1731-1737.	3.9	39
54	Von Willebrand factor C1C2 domain is involved in platelet adhesion to polymerized fibrin at high shear rate. Blood, 2004, 103, 1741-1746.	1.4	38

#	Article	IF	Citations
55	Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices. Thrombosis and Haemostasis, 2014, 112, 1014-1023.	3.4	37
56	Novel Function of Tenascin-C, a Matrix Protein Relevant to Atherosclerosis, in Platelet Recruitment and Activation Under Flow. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 117-124.	2.4	36
57	von Willebrand factor: at the crossroads of bleeding and thrombosis. International Journal of Hematology, 2012, 95, 353-361.	1.6	36
58	ON THE VERSATILITY OF VON WILLEBRAND FACTOR. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013046.	1.3	36
59	A mutation in the gene coding for the sialic acid transporter SLC35A1 is required for platelet life span but not proplatelet formation. Haematologica, 2018, 103, e613-e617.	3.5	36
60	Correction of Bleeding Symptoms in von Willebrand Factorâ€“Deficient Mice by Liver-Expressed von Willebrand Factor Mutants. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 419-424.	2.4	35
61	A Novel Single-Domain Antibody Against von Willebrand Factor A1 Domain Resolves Leukocyte Recruitment and Vascular Leakage During Inflammationâ€”Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1736-1740.	2.4	33
62	In Vivo Analysis of the Role of O-Glycosylations of Von Willebrand Factor. PLoS ONE, 2012, 7, e37508.	2.5	33
63	Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor. Haematologica, 2018, 103, 728-737.	3.5	32
64	A hemophilia A mouse model for the in vivo assessment of emicizumab function. Blood, 2020, 136, 740-748.	1.4	32
65	Neutrophils mediate edema formation but not mechanical allodynia during zymosan-induced inflammation. Journal of Leukocyte Biology, 2014, 96, 133-142.	3.3	31
66	Network-based analysis of omics data: the LEAN method. Bioinformatics, 2017, 33, 701-709.	4.1	29
67	Shear stressâ€independent binding of von Willebrand factorâ€type 2B mutants p.R1306Q & p.V1316M to LRP1 explains their increased clearance. Journal of Thrombosis and Haemostasis, 2015, 13, 815-820.	3.8	28
68	Disrupted filamin A/Î±IIbÎ²3 interaction induces macrothrombocytopenia by increasing RhoA activity. Blood, 2019, 133, 1778-1788.	1.4	27
69	Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity. Scientific Reports, 2016, 6, 37953.	3.3	26
70	Cellular uptake of C4bâ€binding protein is mediated by heparan sulfate proteoglycans and CD91/LDL receptorâ€related protein. European Journal of Immunology, 2008, 38, 809-817.	2.9	25
71	Mutations in the A3 domain of Von Willebrand factor inducing combined qualitative and quantitative defects in the protein. Blood, 2013, 121, 2135-2143.	1.4	25
72	Impact of PI3KÎ± (Phosphoinositide 3-Kinase Alpha) Inhibition on Hemostasis and Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 2041-2053.	2.4	24

#	Article	IF	Citations
73	The von Willebrand factor Tyr2561 allele is a gain-of-function variant and a risk factor for early myocardial infarction. Blood, 2019, 133, 356-365.	1.4	24
74	Efficient Inhibition of Collagen-Induced Platelet Activation and Adhesion by LAIR-2, a Soluble Ig-Like Receptor Family Member. PLoS ONE, 2010, 5, e12174.	2.5	24
75	LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B. JCI Insight, 2016, 1, e88643.	5.0	23
76	Emerging Therapeutic Strategies in the Treatment of Hemophilia A. Seminars in Thrombosis and Hemostasis, 2017, 43, 581-590.	2.7	22
77	Endothelial-driven increase in plasma thrombin generation characterising a new hypercoagulable phenotype in acute heart failure. International Journal of Cardiology, 2019, 274, 195-201.	1.7	22
78	Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor. Blood, 2019, 133, 366-376.	1.4	22
79	Shear rate gradients promote a bi-phasic thrombus formation on weak adhesive proteins, such as fibrinogen in a VWF-dependent manner. Haematologica, 2020, 105, 2471-2483.	3.5	22
80	The VWF/LRP4/Î±VÎ²3-axis represents a novel pathway regulating proliferation of human vascular smooth muscle cells. Cardiovascular Research, 2022, 118, 622-637.	3.8	22
81	The Î±-Chains of C4b-binding Protein Mediate Complex Formation with Low Density Lipoprotein Receptor-related Protein. Journal of Biological Chemistry, 2002, 277, 2511-2516.	3.4	20
82	Singleâ€domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors. EMBO Molecular Medicine, 2020, 12, e11298.	6.9	20
83	Terminal Platelet Production is Regulated by Von Willebrand Factor. PLoS ONE, 2013, 8, e63810.	2.5	20
84	Complete Defect in vWF-cleaving Protease Activity Associated with Increased Shear-induced Platelet Aggregation in Thrombotic Microangiopathy. Thrombosis and Haemostasis, 2002, 87, 808-811.	3.4	19
85	In Vivo Clearance of Human Protein S in a Mouse Model. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2209-2215.	2.4	19
86	Correction of the bleeding time in von Willebrand factor (VWF)â€“deficient mice using murine VWF. Blood, 2007, 109, 2267-2268.	1.4	19
87	A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation. Scientific Reports, 2016, 6, 26306.	3.3	19
88	A factor VIIIâ€“nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation. Blood, 2018, 132, 1193-1197.	1.4	19
89	Weibel-Palade Bodies Orchestrate Pericytes During Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1843-1858.	2.4	19
90	The von Willebrand Factor A1 domain mediates thromboinflammation, aggravating ischemic stroke outcome in mice. Haematologica, 2021, 106, 819-828.	3.5	18

#	Article	IF	Citations
91	von Willebrand factor clearance does not involve proteolysis by ADAMTS-13. Journal of Thrombosis and Haemostasis, 2010, 8, 2338-2340.	3.8	17
92	A mutation of the human EPHB2 gene leads to a major platelet functional defect. Blood, 2018, 132, 2067-2077.	1.4	17
93	A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor. Blood, 2012, 120, 2723-2732.	1.4	16
94	Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA. Haematologica, 2020, 105, 1129-1137.	3.5	15
95	Von Willebrand Factor and Thrombosis: Risk Factor, Actor and Pharmacological Target. Current Vascular Pharmacology, 2013, 11, 448-456.	1.7	15
96	Towards standardization of in vivo thrombosis studies in mice. Journal of Thrombosis and Haemostasis, 2011, 9, 1641-1644.	3.8	14
97	Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia. Blood, 2019, 134, 1632-1644.	1.4	14
98	A compact integrated microfluidic oxygenator with high gas exchange efficiency and compatibility for long-lasting endothelialization. Lab on A Chip, 2021, 21, 4791-4804.	6.0	14
99	Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence. Haematologica, 2019, 104, 2493-2500.	3.5	13
100	Platelet Functions are Decreased in Obesity and Restored after Weight Loss: Evidence for a Role of the SERCA3-Dependent ADP Secretion Pathway. Thrombosis and Haemostasis, 2019, 119, 384-396.	3.4	13
101	von Willebrand disease: what does the future hold?. Blood, 2021, 137, 2299-2306.	1.4	13
102	Molecular characterization of Iranian patients with type 3 von Willebrand disease. Haemophilia, 2009, 15, 1058-1064.	2.1	11
103	Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions. Blood, 2017, 129, 2443-2454.	1.4	11
104	Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor. Gene Therapy, 2023, 30, 245-254.	4.5	11
105	Mouse models of von Willebrand disease. Journal of Thrombosis and Haemostasis, 2009, 7, 61-64.	3.8	10
106	Two residues in the activation peptide domain contribute to the half-life of factor X in vivo. Journal of Thrombosis and Haemostasis, 2010, 8, 1651-1653.	3.8	10
107	Haemorrhagic and thrombotic diatheses in mouse models with thrombocytosis. Thrombosis and Haemostasis, 2015, 113, 414-425.	3.4	10
108	NAADP/SERCA3-Dependent Ca ²⁺ Stores Pathway Specifically Controls Early Autocrine ADP Secretion Potentiating Platelet Activation. Circulation Research, 2020, 127, e166-e183.	4.5	10

#	Article	IF	Citations
109	Coagulation Factor X Interaction with Macrophages through Its N-Glycans Protects It from a Rapid Clearance. PLoS ONE, 2012, 7, e45111.	2.5	10
110	Elevated plasma von Willebrand factor in a murine model of severe hyperhomocysteinemia. Thrombosis and Haemostasis, 2003, 90, 362-363.	3.4	9
111	Assessment of endothelial damage and cardiac injury in a mouse model mimicking thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2016, 14, 1917-1930.	3.8	9
112	Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami. Journal of Thrombosis and Haemostasis, 2016, 14, 1725-1735.	3.8	9
113	Protein kinase C signaling dysfunction in von Willebrand disease (p.V1316M) type 2B platelets. Blood Advances, 2018, 2, 1417-1428.	5.2	9
114	Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X. Blood, 2016, 127, 778-786.	1.4	8
115	Camelidâ€derived singleâ€chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1087-1110.	2.3	8
116	Von Willebrand factor in vascular pathophysiology. Pathologie Et Biologie, 2003, 51, 395-396.	2.2	7
117	Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpura in mice. Blood, 2014, 123, 3344-3353.	1.4	6
118	LDL receptor-related protein 1 contributes to the clearance of the activated factor VII-antithrombin complex. Journal of Thrombosis and Haemostasis, 2016, 14, 2458-2470.	3.8	6
119	Measuring betaâ€galactose exposure on platelets: Standardization and healthy reference values. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 813-822.	2.3	6
120	Development and characterization of singleâ€domain antibodies neutralizing protease nexinâ€1 as tools to increase thrombin generation. Journal of Thrombosis and Haemostasis, 2020, 18, 2155-2168.	3.8	6
121	Von Willebrand Factor Gene Variants Associate with Herpes simplex Encephalitis. PLoS ONE, 2016, 11, e0155832.	2.5	6
122	Biological outcome and mapping of total factor cascades in response to HIF induction during regenerative angiogenesis. Oncotarget, 2016, 7, 12102-12120.	1.8	6
123	von Willebrand disease biology. Haemophilia, 2012, 18, 141-147.	2.1	5
124	Platelet von Willebrand factor: sweet resistance. Blood, 2013, 122, 4006-4007.	1.4	5
125	Use of a thrombopoietin receptor agonist in von Willebrand disease type 2B (p.V1316M) with severe thrombocytopenia and intracranial hemorrhage. Platelets, 2017, 28, 518-520.	2.3	5
126	VWF clearance: itâ€™s glycomplicated. Blood, 2018, 131, 842-843.	1.4	5

#	Article	IF	Citations
127	Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 407-428.	2.3	5
128	A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A. Thrombosis and Haemostasis, 2019, 119, 1981-1993.	3.4	5
129	In vivo modulation of a dominantâ€negative variant in mouse models of von Willebrand disease type 2A. Journal of Thrombosis and Haemostasis, 2021, 19, 139-146.	3.8	5
130	Carboxypeptidase E does not mediate von Willebrand factor targeting to storage granules. European Journal of Cell Biology, 1999, 78, 884-891.	3.6	4
131	von Willebrand factor A1 domain: stuck in the middle. Journal of Thrombosis and Haemostasis, 2007, 5, 1361-1362.	3.8	4
132	Apoptotic Platelet Events Are Not Observed in Severe von Willebrand Disease-Type 2B Mutation p.V1316M. PLoS ONE, 2015, 10, e0143896.	2.5	4
133	Illustrated Stateâ€ofâ€theâ€Art Capsules of the ISTH 2022 Congress. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12747.	2.3	4
134	In vivo MRI and ex vivo quantification of iron and Kupffer cells demonstrate residual phagocytic activity in mouse liver after a gadolinium chloride injection. Biochimie, 2010, 92, 1343-1353.	2.6	3
135	VON WILLEBRAND FACTOR ABNORMALITIES STUDIED IN THE MOUSE MODEL: WHAT WE LEARNED ABOUT VWF FUNCTIONS. Mediterranean Journal of Hematology and Infectious Diseases, 2013, 5, e2013047.	1.3	3
136	Removal of Mannose-Ending Glycan at Asn2118 Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells. Frontiers in Immunology, 2020, 11, 393.	4.8	3
137	Gain-of-Function Variant p.Pro2555Arg of von Willebrand Factor Increases Aggregate Size through Altering Stem Dynamics. Thrombosis and Haemostasis, 2020, , .	3.4	3
138	New insights into regulation of Î±IIbÎ²3 integrin signaling by filamin A. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12672.	2.3	2
139	A singleâ€domain antibody that blocks factorVIIa activity in the absence but not presence of tissue factor. Journal of Thrombosis and Haemostasis, 2019, 17, 2035-2046.	3.8	1
140	The Von Willebrand Factor Tyr2561 Allele Is a Gain-of-Function Variant and a Potential Risk Factor for Early Myocardial Infarction. Blood, 2018, 132, 2459-2459.	1.4	1
141	A Combination of Two Variants p. (Val510 =) and p. (Pro2145Thrfs * 5), Responsible for von Willebrand Disease Type 3 in a Caribbean Patient. TH Open, 2020, 04, e318-e321.	1.4	1
142	How to keep the FVIII/VWF complex in the circulation. Haematologica, 2021, , .	3.5	1
143	Identification of von Willebrand factor D4 domain mutations in patients of Afroâ€Caribbean descent: In vitro characterization. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12737.	2.3	1
144	Pas de deux between VWF and ADAMTS13. Blood, 2008, 111, 3306-3307.	1.4	0

#	Article	IF	Citations
145	Antibody-Based Protection of von Willebrand Factor Degradation. JACC: Heart Failure, 2016, 4, 518.	4.1	0
146	Plaquettes et endothÃ©lium: un mariage de raison.. Medecine/Sciences, 2001, 17, 252.	0.2	0
147	Functional and clinical aspects of the anti-hemophilic bispecific antibody emicizumab. Hematologie, 2020, 26, 328-342.	0.0	0
148	TaSER: Combining forces to stop the clot. Journal of Thrombosis and Haemostasis, 2022, 20, 293-295.	3.8	0
149	A thrombopoietin receptor agonist to rescue an unusual platelet transfusion-induced reaction in a p.V1316M-associated von Willebrand disease type 2B patient. Therapeutic Advances in Hematology, 2022, 13, 204062072210768.	2.5	0
150	Antithrombotic potential of a singleâ€domain antibody enhancing the activated protein Câ€cofactor activity of protein S. Journal of Thrombosis and Haemostasis, 2022, , .	3.8	0